We use molecular brain imaging to find new therapeutic targets and biomarkers for psychiatric and neurodegenerative disease, tracking how brain circuits respond to disease and therapy from rodents to large animals.
Led by Anne M. Landau, Associate Professor, Department of Clinical Medicine, Aarhus University.
Three priorities anchor the lab, supported by a shared molecular-imaging toolkit spanning PET tracers, MRI, disease models, and tissue analysis.
G protein-coupled receptor 6 (GPR6), a receptor on dopamine-signaling neurons, as a novel therapeutic target in depression, using the GPR6-targeting drug CVN424.
SV2A / [11C]UCB-J PET to image synaptic change in disease models and in response to therapies, including deep brain stimulation, exercise, and S-ketamine.
Developing imaging biomarkers of neuroinflammation in neurodegenerative and psychiatric disease.
A broader tracer toolkit beyond SV2A: dopamine synthesis (FDOPA), metabolism (FDG), and receptor autoradiography.
Rodent, large-animal (Göttingen minipig), and transgenic mouse models of psychiatric and neurodegenerative disease.
Pairing PET with in vivo and ex vivo MRI (microstructure, diffusion), behavior, and tissue analysis to read out brain circuits.
The Landau Lab develops and validates molecular brain imaging to track how neural circuits adapt across disease, injury, and therapy. Working across rodent, large-animal, and genetic models, we combine PET with MRI, behavior, and tissue analysis under a consistent translational aim: readouts that can move from the bench toward the clinic.
The group is part of the Translational Neuropsychiatry Unit at the Department of Clinical Medicine, Aarhus University.
A catalogue of the lab's published work, figure-forward, is in preparation.
For collaborations, student projects, or questions about our imaging work.
email alandau@clin.au.dk
place Department of Clinical Medicine, Aarhus University, Denmark
profile Anne M. Landau at TNU, Aarhus University